Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 11/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582330 | 0.86 | CSNK2A1 (0.48) | CSNK2A1CSNK2A2CSNK2BPDGFRBPDGFRA | |
| SCHEMBL5582036 | 0.85 | PTPN11 (0.43) | PTPN11CSNK2A1CSNK2A2CSNK2BPDGFRB | |
| SCHEMBL5582010 | 0.85 | CSNK2A2 (0.47) | CSNK2A1CSNK2A2CSNK2BPDGFRBPDGFRA | |
| SCHEMBL5582325 | 0.84 | KMO (0.43) | CSNK2A1CSNK2A2CSNK2BPTK2 | |
| SCHEMBL5582255 | 0.83 | CSNK2A1 (0.43) | CSNK2A1CSNK2A2CSNK2BPDGFRBPDGFRA | |
| SCHEMBL5582162 | 0.83 | PTK2 (0.42) | CSNK2A1CSNK2A2CSNK2BPTK2 | |
| SCHEMBL5582212 | 0.83 | CSNK2A1 (0.49) | PDE4APDE4BPDE4CPDE4DCSNK2A1 | |
| SCHEMBL5582062 | 0.82 | MKNK1 (0.44) | CSNK2A1CSNK2A2CSNK2BPTK2 | |
| SCHEMBL5582013 | 0.82 | CSNK2A1 (0.51) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL5585115 | 0.82 | PIK3CD (0.39) | PTPN11PDE4BPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | KYOWA HAKKO KOGYO CO.,LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1726584-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | AGTR2, ABL1, AGTR1 | PTPN11 542/4885PDE4A 1628/4885PDE4B 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.